SCHEMBL956476

SCHEMBL956476

Cc1nc2ccc(Cl)nn2c1C(N)=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
POLB P06746 2/20 0.43
GAA P10253 2/20 0.43
PRMT5 O14744 1/20 0.39
WDR77 Q9BQA1 1/20 0.39
TGFBR1 P36897 3/20 0.39
KDM4E B2RXH2 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TNF P01375 1/20 0.38
NTRK1 P04629 2/20 0.36
KMT2A Q03164 3/20 0.36
CDK5 Q00535 3/20 0.35
ACVR1 Q04771 2/20 0.35
AURKA O14965 1/20 0.35
CSF1R P07333 1/20 0.35
RET P07949 1/20 0.35
LTK P29376 1/20 0.35
CSNK1A1 P48729 1/20 0.35
CDK8 P49336 1/20 0.35
CLK2 P49760 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6617429 0.86 ALDH1A1 (0.40) ALDH1A1POLBGAAPRMT5WDR77
SCHEMBL954064 0.84 ALDH1A1 (0.39) ALDH1A1POLBGAAPRMT5WDR77
SCHEMBL5270074 0.80 NTRK1 (0.41) ALDH1A1PRMT5WDR77KDM4ENTRK1
SCHEMBL953671 0.80 MAPK1 (0.52) ALDH1A1POLBGAAKDM4ESMN1; SMN2
SCHEMBL15538674 0.78 PDE10A (0.45) ALDH1A1GAAPRMT5WDR77KDM4E
SCHEMBL15562881 0.77 MEN1 (0.38) ALDH1A1POLBGAAKDM4ESMN1; SMN2
SCHEMBL1203501 0.76 RAB9A (0.53) GAASMN1; SMN2KMT2ALMNANPC1
SCHEMBL18339005 0.76 ALDH1A1 (0.39) ALDH1A1POLBGAAPRMT5WDR77
SCHEMBL12798307 0.74 KDM4E (0.47) ALDH1A1PRMT5WDR77KDM4ESMN1; SMN2
SCHEMBL15562597 0.74 MAPK14 (0.40) ALDH1A1GAAPRMT5WDR77KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9139589-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
US-9090601-B2 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
EP-2391619-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS Millennium Pharmaceuticals, Inc. (US) 2011-12-07 EP disclosed
US-20110003807-A1 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003806-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
WO-2010090716-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003807-A1 Thiazole derivatives MTOR, RICTOR, AKT2 ALDH1A1 1687/4885POLB 4355/4885GAA 1418/4885
US-20110003806-A1 Heteroaryls and uses thereof RICTOR, MTOR, AKT1S1 ALDH1A1 728/4885POLB 2653/4885GAA 1693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.